HAIKOU CITY, China, May 6 /PRNewswire-Asia/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a leading fully-integrated specialty pharmaceuticals company in China, today announced that it will participate in the following investor conferences:
Piper Jaffray 7th Annual China Growth Conference on Thursday, May 13, 2010 in New York City. Management is scheduled to present at 9:30 am ET on Thursday, May 13, and will be available to meet with institutional investors throughout the conference.
Rodman & Renshaw Annual Global Investment Conference on May 16-18, 2010 at the Grosvenor House Hotel in London, UK. Management is scheduled to present at 10:40 am BST on Monday, May 17, and will be available to meet with institutional investors throughout the conference.
Brean Murray, Carret & Co. 2010 Life Sciences Summit on Monday, May 17, 2010 at The Grand Hyatt Hotel in New York City. Management is scheduled to participate in the Winners and Losers of China Healthcare Reform panel at 2:00 pm ET and will be available to meet with institutional investors throughout the conference.
Oppenheimer & Co.'s 4th Annual China Dragon Call Conference on May 18-20, 2010 in New York City. Management is scheduled to present at 1:10 pm ET on Tuesday, May 18, and will be available to meet with institutional investors throughout the conference.
For further details, please contact your respective institutional sales representative.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across 30 provinces, municipalities and autonomous regions. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
For more information, please contact:
China Pharma Holdings, Inc.
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
CCG Investor Relations
Lei Huang, Account Manager
Phone: +1-646-833-3417 (New York)
Email: lei.huang@ccgir.com
Vivian Chen, Sr. Market Intelligence Exec.
Phone: +1-646-701-7445(New York)
Email: vivian.chen@ccgir.com
